Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
McKesson
Express Scripts
Cipla
Covington
Baxter
Deloitte
Johnson and Johnson
Queensland Health

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

« Back to Dashboard

Clinical Trials for Hydralazine Hydrochloride; Isosorbide Dinitrate

Trial ID Title Status Sponsor Phase Summary
NCT01516346 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction Active, not recruiting National Institute on Aging (NIA) Phase 2 The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.
NCT01516346 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction Active, not recruiting University of Pennsylvania Phase 2 The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.
NCT01516346 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction Active, not recruiting Corporal Michael J. Crescenz VA Medical Center Phase 2 The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.
NCT01822808 Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure Active, not recruiting Momentum Research, Inc. Phase 3 To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes, symptoms, cardiac parameters and functional status of African patients hospitalized with AHF and left ventricular dysfunction during 24 weeks of therapy. Administration of hydralazine/nitrates will be superior to placebo administration in reducing HF readmission or death, improving dyspnoea, reducing blood pressure and brain natriuretic peptide (BNP) in African patients admitted with AHF and left ventricular dysfunction.
NCT01822808 Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure Active, not recruiting University of Cape Town Phase 3 To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes, symptoms, cardiac parameters and functional status of African patients hospitalized with AHF and left ventricular dysfunction during 24 weeks of therapy. Administration of hydralazine/nitrates will be superior to placebo administration in reducing HF readmission or death, improving dyspnoea, reducing blood pressure and brain natriuretic peptide (BNP) in African patients admitted with AHF and left ventricular dysfunction.
NCT02228408 Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD Not yet recruiting Brigham and Women's Hospital Phase 4 This study is a pilot study designed to compare the safety and cardiovascular effects of 26 weeks of combination hydralazine/isorsorbide dinitrate therapy with amlodipine therapy in patients receiving chronic hemodialysis. The investigators hypothesize that treatment of chronic hemodialysis (ESRD) patients with a combination of hydralazine/isosorbide dinitrate compared with amlopdipine is safe and that it will improve heart function as well blood flow/blood vessel supply.
NCT02305095 Genomic Response Analysis of Heart Failure Therapy in African Americans Recruiting University of Pittsburgh N/A The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine (FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction (HFrEF) when compared to similar white cohorts. This study will seek to confirm the previous genetic sub-study from AHeFT which suggested a functional polymorphism of guanine nucleotide binding protein beta polypeptide 3 subunit (GNB3), C825T in exon 10, influences the therapeutic efficacy of FDC I/H. This study will initiate treatment with FDC I/H in 500 self designated African American subjects with systolic heart failure. They will be followed for up to two years on therapy. Clinical outcomes (survival, heart failure hospitalizations, and change in quality of life) on FDC I/H will be compared by GNB3 genotype subset. The hypothesis to be confirmed is that subjects homozygous for the T allele (those with the GNB3 TT genotype which is present in approximately 50% of black subjects) demonstrate enhanced therapeutic benefit from FDC I/H.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hydralazine Hydrochloride; Isosorbide Dinitrate

Condition Name

Condition Name for Hydralazine Hydrochloride; Isosorbide Dinitrate
Intervention Trials
Heart Failure 4
Diabetes 1
Congestive Heart Failure 1
Chronic Hemodialysis (ESRD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydralazine Hydrochloride; Isosorbide Dinitrate
Intervention Trials
Heart Failure 5
Syndrome 1
Cardio-Renal Syndrome 1
Ventricular Dysfunction, Left 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydralazine Hydrochloride; Isosorbide Dinitrate

Trials by Country

Trials by Country for Hydralazine Hydrochloride; Isosorbide Dinitrate
Location Trials
United States 22
Singapore 1
South Africa 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydralazine Hydrochloride; Isosorbide Dinitrate
Location Trials
Georgia 2
Alabama 2
Massachusetts 2
Pennsylvania 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydralazine Hydrochloride; Isosorbide Dinitrate

Clinical Trial Phase

Clinical Trial Phase for Hydralazine Hydrochloride; Isosorbide Dinitrate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydralazine Hydrochloride; Isosorbide Dinitrate
Clinical Trial Phase Trials
Recruiting 3
Active, not recruiting 2
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydralazine Hydrochloride; Isosorbide Dinitrate

Sponsor Name

Sponsor Name for Hydralazine Hydrochloride; Isosorbide Dinitrate
Sponsor Trials
University of Pennsylvania 1
Changi General Hospital 1
Danish Heart Foundation 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydralazine Hydrochloride; Isosorbide Dinitrate
Sponsor Trials
Other 15
NIH 1
Industry 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Healthtrust
QuintilesIMS
Moodys
Chinese Patent Office
Baxter
Medtronic
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.